major depressive disorder
Conditions
Interventions
Two groups:Light therapy group will receive a 5-week daily light therapy. TAU subjects will also be prescribed with a 5-week placebo intervention.
Sponsors
The Chinese University of Hong Kong
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-65 years; 2. Is capable of giving informed consent; 3. Meet diagnostic criteria of major depressive disorder (MDD) by the Mini-Neuropsychiatric Interview (MINI); 4. Score at least 14 on the 17-item Hamilton Rating Scale for Depression (HAM-D17); 5. Evening chronotype.
Exclusion criteria
Exclusion criteria: 1. Major Depressive Disorder fulfilling the Seasonal Pattern Specifier of the DSM-V (Seasonal Affective Disorder); 2. A current diagnosis of substance abuse or dependence; 3. A current or past history of manic or hypomanic episode, schizophrenia, personality disorder, mental retardation, or organic mental disorder; 4. Significant risk of suicide in the opinion of the investigator, or has moderate or above level of suicidality as assessed in the MINI Suicidality Module, or has made a suicide attempt in the past three months; 5. History of light induced migraine/ epilepsy; 6. Current use of photosensitizing medications, e.g. St John's wart; 7. Presence of eye disease: e.g. retinal blindness, severe cataract, glaucoma; 8. Drugs that may interfere with circadian rhythm, i.e. lithium, exogenous melatonin, melatonergic antidepressants within past 3 months; 9. Shift worker; 10. Trans-meridian flight in the past 3 months and during study; 11. Enrolment in any other clinical trial investigational products within one month at the entry of the study; 12. Significant medical condition/ hearing impairment/ speech deficit lead to incapability in completing clinical interview.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| remission rate as defined by the HAM-D 17 score;the depressive symptoms severity via Structured Interview Guide for the Hamilton Depression Rating Scale with Atypical Depression Supplement (SIGH-ADS); | — |
Secondary
| Measure | Time frame |
|---|---|
| anxiety symptoms (HAM-A, HADS);insomnia symptoms (ISI);suicidal ideation (BSSI);fatigue (CFS);quality of life (SF-36);sleep pattern; | — |
Countries
China
Contacts
Public ContactProf. Wing Yun Kwok
The Chinese University of Hong Kong
Outcome results
None listed